Gene Editing Collaboration and Licensing Deals 2016-2024


Gene Editing Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2024

Publication date
May 2024
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

Gene Editing Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene editing deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of gene editing deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter gene editing deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 354 gene editing deals announced since 2016 including financial terms where available including links to online deal records of actual gene editing partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of gene editing dealmaking. 

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in gene editing dealmaking since 2016.

Chapter 3 provides an overview of the leading gene editing deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in gene editing dealmaking with a brief summary followed by a comprehensive listing of gene editing deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of gene editing deals signed and announced since Jan 2016, where a contract document is available in the public domain. 

Chapter 6 provides a comprehensive and detailed review of gene editing partnering deals signed and announced since Jan 2016. The chapter is organized by specific gene editing technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in gene editing deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Gene Editing Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse gene editing collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Report scope

Gene Editing Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of gene editing trends and structure of deals entered into by leading biopharma companies worldwide.

Gene Editing Collaboration and Licensing Deals includes:
•    Trends in gene editing dealmaking in the biopharma industry
•    Directory of gene editing deal records covering pharmaceutical and biotechnology
•    The leading gene editing deals by value
•    Most active gene editing licensing dealmakers

Gene Editing Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

•    What are the precise rights granted or optioned?
•    What is actually granted by the agreement to the partner company?
•    What exclusivity is granted?
•    What is the payment structure for the deal?
•    How are sales and payments audited?
•    What is the deal term?
•    How are the key terms of the agreement defined?
•    How are IPRs handled and owned?
•    Who is responsible for commercialization?
•    Who is responsible for development, supply, and manufacture?
•    How is confidentiality and publication managed?
•    How are disputes to be resolved?
•    Under what conditions can the deal be terminated?
•    What happens when there is a change of ownership?
•    What sublicensing and subcontracting provisions have been agreed?
•    Which boilerplate clauses does the company insist upon?
•    Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
•    Which jurisdiction does the company insist upon for agreement law?

Gene Editing Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse gene editing collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in gene editing dealmaking
2.1. Introduction
2.2. Gene editing deals over the years
2.3. Most active gene editing dealmakers
2.4. Gene editing deals by deal type
2.5. Gene editing deals by therapy area
2.6. Gene editing deals by industry sector
2.7. Deal terms for gene editing deals
2.7.1 Gene editing deals headline values
2.7.2 Gene editing deal upfront payments
2.7.3 Gene editing deal milestone payments
2.7.4 Gene editing royalty rates

Chapter 3 – Leading gene editing deals
3.1. Introduction
3.2. Top gene editing deals by value

Chapter 4 – Most active gene editing dealmakers
4.1. Introduction
4.2. Most active gene editing dealmakers
4.3. Most active gene editing deals company profiles

Chapter 5 – Gene editing contracts dealmaking directory
5.1. Introduction
5.2. Gene editing contracts dealmaking directory

Chapter 6 – Gene editing dealmaking by technology type

Deal directory

Deal directory – Gene editing deals by company A-Z
Deal directory – Gene editing deals by deal type
Deal directory – Gene editing deals by therapy area

Deal type definitions

About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Gene editing deals since 2016
Figure 2: Active gene editing dealmaking activity – 2016 - 2024
Figure 3: Gene editing deals by deal type since 2016
Figure 4: Gene editing deals by therapy area since 2016
Figure 5: Gene editing deals by industry sector since 2016
Figure 6: Gene editing deals with a headline value
Figure 7: Gene editing deals with an upfront value
Figure 8: Gene editing deals with a milestone value
Figure 9: Gene editing deals with a royalty rate value
Figure 10: Top gene editing deals by value since 2016
Figure 11: Most active gene editing dealmakers 2016 - 2024
Figure 12: Gene editing deals by technology type since 2016

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

2seventy bio, 4D Molecular Therapeutics, 221b Foundation, Abbvie, Acrobat Genomics, Acuitas Therapeutics, Adaptimmune, Advanced Biological Innovation and Manufacturing, Adverum Biotechnologies, Aelian Biotechnology, Affini-T Therapeutics, Agribody Technologies, Albany Molecular Research, ALBOT Technologies, Alcyone Lifesciences, Aldevron, AlgenScribe, Allele Biotechnology and Pharmaceuticals, Allergan, Allogene Therapeutics, American Skin Association, Amfora, AmplyCell, Anagenesis Biotechnologies, Ankarys Therapeutics, Anocca AB, Applied Biological Materials, Applied StemCell, Arbor Biotechnologies, Arbutus, Arctoris, Artisan Bio, ASC Therapeutics, Asklepios Biopharmaceutical, Astellas Pharma, AstraZeneca, ATUM, Avectas, Avellino Labs, Avita Therapeutics, Axcelead Drug Discovery Partners, Axxam, B-MoGen Biotechnologies, BASF, Batavia Biosciences, Baxalta, Bayer, Bayer CropScience, Beam Therapeutics, Ben-Gurion University, Benson Hill Biosystems, Berkeley Lights, Beth Israel Deaconess Medical Center, Bill and Melinda Gates Foundation, Binx Health, Bio-Techne, BioCentriq, Biogen, Bioheuris, Biomedical Advanced Research and Development Authority, Bioneer, Bluebird Bio, BlueRock Therapeutics, Bone Therapeutics, BRAIN Biotech, BrainXell, Brigham and Women's Hospital, Bristol-Myers Squibb, Broad Institute, Brooklyn ImmunoTherapeutics, C4X Discovery, Cabaletta Bio, California Institute for Regenerative Medicine, California Institute of Technology, Calyxt, CANbridge Pharmaceuticals, Cancer Research UK, Canopy Biosciences, Capsida Biotherapeutics, CARB-X, Caribou Biosciences, Casebia Therapeutics, CasZyme, Catalent, Catamaran Bio, Cellecta, Cellectis, Cellibre, Cellistic, Cell Microsystems, Cellular Engineering Technologies, Center for Human Genetics and Laboratory Medicine, Central Institute for Experimental Animals, Cepheid, CGA 369, Charles River Laboratories, CHDI Foundation, China Agricultural University, CHUM Research Centre, CIC nanoGUNE, Cimeio Therapeutics, City of Hope, Coastar Therapeutics, COBO Technologies, Cocrystal Pharma, Codiak BioSciences, Colors Farm, Columbia University, Columbia University Medical Center, Corteva Agriscience, Cosmo Bio, CRISPR Therapeutics, Crown Bioscience, Cumming, Curia, Cyrus Biotechnology, CytoLynx Therapeutics, Cytosurge, CYTOVIA Therapeutics, Daiichi Sankyo, Dana-Farber Cancer Institute, Dartmouth-Hitchcock Medical Center, DefiniGEN, Demeetra AgBio, Department of Defense, Desktop Genetics, Dow AgroSciences, Duke University, DuPont, DuPont Pioneer, EdiGene, Editas Medicine, eGenesis, Element Biosciences, Eligo Bioscience, Eli Lilly, EMBRAPA, EmendoBio, Emendo Biotherapeutics, Emory University, ERS Genomics, Evogene, Evolva, Evotec, Excision BioTherapeutics, Exonics Therapeutics, Factor Bioscience, FASMAC, Food and Drug Administration (FDA), Frederick National Laboratory For Cancer Research, Friedreichs Ataxia Research Alliance, Fujifilm, Fujifilm Diosynth Biotechnologies, Fulcrum Therapeutics, FuturaGene, G+FLAS Life Sciences, GDM Seeds, Geisel School of Medicine at Dartmouth, GEMoaB, GenAhead Bio, GenEdit, Genentech, GeneThera, Genetic Information Research Institute, Genevant Sciences, GenKOre, genOway, GenScript Biotech, Gensus, Genus, GenVec, Gilead Sciences, Ginkgo BioWorks, Goethe University Frankfurt, Great Ormond Street Hospital (GOSH), Greenlight Biosciences, GSK, GSK Consumer Healthcare, Harpe Bioherbicide Solutions, Harvard Medical School, Harvard Stem Cell Institute, Harvard University, HebeCell, Helen F Graham Cancer Center, Helmholtz Zentrum Munchen, Hillstream BioPharma, Homology Medicines, Horizon Discovery, Horizon Pharma plc, Humanigen, Hunterian Medicine, IBM Watson Health, IDbyDNA, IDEAYA Biosciences, iECURE, Illumina, Immatics Biotechnologies, ImmunoChina Pharmaceuticals, Immusoft, Implant Therapeutics, InnoBation, Innovative Genomics Initiative (IGI), Inscripta, Integra Therapeutics, Intellia Therapeutics, Ionis Pharmaceuticals, Iovance Biotherapeutics, Israeli National Authority for Technological Innovation, Jackson Laboratory, Janssen Pharmaceuticals, Japan SLC, Johns Hopkins University, Jumpcode Genomics, Kantonsspital St. Gallen, Keck Graduate Institute of Applied Life Sciences, Kiromic Biopharma, Kite Pharma, Knudra Transgenics, KromaTiD, KSQ Therapeutics, Kytopen, Kyverna Therapeutics, Lepton Pharmaceuticals, Les Laboratoires Servier, Life Edit Therapeutics, Locus Biosciences, LogicBio Therapeutics, LogicInk, Logomix, Lonza, Ludwig Institute for Cancer Research, Mammoth Biosciences, Marina Biotech, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Massachusetts Institute of Technology, MaSTherCell, Max-Delbruck Center for Molecular Medicine, Maxcyte, Mayo Clinic, MEDiC Life Sciences, MediGene, Meiogenix, Merck and Co, Merck KGaA, Metagenomi, MilliporeSigma, Modalis Therapeutics, Moderna, Molecular Templates, Monsanto, Muscular Dystrophy Association, Mustang Bio, Myeloid Therapeutics, NanoString Technologies, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institutes of Health, National Kidney Foundation, National Organization for Rare Disorders, Ncardia, Neon Therapeutics, Netherlands Cancer Institute, New England Biolabs, New York University School of Medicine, Nippon Gene, Nkarta Therapeutics, NMI Natural and Medical Sciences Institute, Nomad Bioscience, Novartis, Novellus Biopharma, NovellusDx, Novellus Therapeutics, Novome Biotechnologies, Novo Nordisk, Nrgene, Nuvisan Pharma Services, Obsidian Therapeutics, ONK Therapeutics, Ono Pharmaceutical, Oregon Health Sciences University, Origin Agritech, Otsuka, Oxford Genetics, Oxford Nanopore Technologies, Pairwise Plants, Parent Project Muscular Dystrophy, Paul Ehrlich Institute, Pfizer, PhenoVista Biosciences, Pioneer Hi-Bred, Plant Bioscience Limited, Pluristem Therapeutics, Pluristyx, Poseida Therapeutics, Precision BioSciences, Predictive Oncology, Prevail Therapeutics, Prime Medicine, ProBioGen, Promega, Pro Pharmaceuticals, Proventus Bio, Qihan Biotech, ReCode Therapeutics, Regeneron Pharmaceuticals, Repare Therapeutics, Revvity, Ricoh, Roche, Roche Diagnostics, Roivant Sciences, Rokline Health Concepts, Rosetta Biosciences, Rutgers University, Saint Louis University, Sana Biotechnology, Sangamo Therapeutics, Sanofi, San Raffaele Scientific Institute, Santa Cruz Biotechnology, Sarepta Therapeutics, Sciex, SCM Pharma, Scribe Therapeutics, Seattle Childrens Research Institute, Selecta Biosciences, SeQure Dx, Setsuro Tech, Shape Therapeutics, Sherlock Biosciences, Shoreline Biosciences, Sigma-Aldrich, SiSaf, Sohm, SparingVision, Sphere Fluidics, Stanford University School of Medicine, StemSight, StrideBio, Sumitomo Pharmaceuticals, Synbal, Syngene International, Syngenta, Syngulon, Synthego, Taconic Biosciences, Takeda Pharmaceutical, Takeda Ventures, Tango Therapeutics, Target ALS Foundation, TCR2 Therapeutics, Telesis Bio, The Human Protein Atlas, The New York Stem Cell Foundation, Thomas Jefferson University, Thrive Bioscience, Tolo Biotech, Toolgen, TransCode Therapeutics, Transomic Technologies, Tropic Biosciences, Twist Bioscience, Ulster University, Universal Cells, University of Alabama, University of Alabama at Birmingham, University of Arkansas, University of British Columbia, University of California, Davis, University of California Berkeley, University of California Los Angeles, University of California San Francisco, University of Colorado, University of Colorado Denver, University of Edinburgh, University of Freiburg, University of Illinois, University of Iowa, University of Kansas, University of Massachusetts, University of Massachusetts Medical School, University of Minnesota, University of Nebraska, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Texas, University of Texas Southwestern Medical Center, University of Tokyo, University of Utah, University of Washington, University of Wisconsin, University of Wisconsin-Madison, US Department of Agriculture, Vectalys, Ventana Medical Systems, Vertex Pharmaceuticals, Verve Therapeutics, Vesigen Therapeutics, VIB, Vir Biotechnology, Virginia Commonwealth University, Vivlion, Vor Biopharma, Voyager Therapeutics, Wageningen University, Wake Forest University, Washington University in St Louis, Weill Cornell Medical College, Willow Biosciences, Yale School of Medicine, Yale University, Yield10 Bioscience, ZeClinics

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.